PTC Therapeutics, Inc.

PTCT Healthcare Biotechnology

PTC Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.7 billion, up 114.5% from fiscal 2024. In the quarter to June 2026, revenue grew 101.6%, EPS grew 221.7%, free cash flow grew 295.7% and total debt rose 21.6%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

59.24 1.75 −2.87%
Market cap
$5.1B
P/E
0.0×
Fwd P/E
110×
Dividend yield
—
F-score
7/9
Altman Z
1.86
Beneish M
−1.48
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

(124.24%) (104.75%) 101.97% 20.64%
Piotroski F-Score
7 7 1 2
ROA
33.51% 29.66% (6.76%) (1.30%)
ROIC
90.05% 121.13% (6.74%) 15.16%
Return on Tangible Assets
62.72% 50.16% (13.50%) (2.02%)
Average Days of Receivables
41.66 38.30 97.05 86.49
Free Cash Flow per Share
5.69 8.83 (5.85) (3.62)
Free Cash Flow
446.32 702.41 (482.67) (300.25)
Other line items

Show all line items

Columns are period end dates